文献速递眼底病与葡萄膜炎

比较抗代谢药物治疗中间型、后型和全葡萄膜炎的随机临床试验生活质量结局

Quality-of-Life Outcomes From a Randomized Clinical Trial Comparing Antimetabolites for Intermediate, Posterior, and Panuveitis.
PubMed 文献 · Am J Ophthalmol · 2017-04-14

这项多中心区组随机试验的二次分析纳入印度两家Aravind眼科医院的80例非感染性中间型、后型或全葡萄膜炎患者,随机接受口服甲氨蝶呤25mg每周或口服吗替麦考酚酯1g每日两次治疗并随访6个月。结果显示IND-VFQ评分平均提高9.2分,SF-36心理成分摘要评分降低2.3分、活力亚量表降低3.5分,两治疗组间生活质量评分无差异。

要点

  • IND-VFQ评分从入组至6个月平均提高9.2分(95%CI:4.9,13.5,P=.0001)。
  • SF-36心理成分摘要评分降低2.3分(95%CI:-4.4,-0.1,P=.04),活力亚量表降低3.5分(95%CI:-5.6,-1.4,P=.001)。
  • 两治疗组间生活质量评分无差异,视力每提高5个字母IND-VFQ评分改善3.2分(95%CI:1.9,4.3;P<.001)。

核心结论

  • 尽管葡萄膜炎治疗与视力和视觉相关生活质量提高相关,但患者报告的身体健康在治疗6个月后无变化,心理健康下降。
  • 尽管视觉结局改善,接受全身免疫抑制治疗的葡萄膜炎患者可能经历心理健康相关生活质量的恶化。

研究设计与样本

  • 多中心区组随机临床试验的二次分析。
  • 纳入印度马杜赖和哥印拜陀Aravind眼科医院的80例非感染性中间型、后型或全葡萄膜炎患者。
  • 患者随机接受口服甲氨蝶呤25mg每周或口服吗替麦考酚酯1g每日两次,每月随访共6个月。
  • 在入组时和6个月时(或早期治疗失败时提前)获取最佳矫正视力、印度视觉功能问卷(IND-VFQ)和医学结局研究36项简表调查(SF-36)。

主要发现

  • IND-VFQ评分从试验入组至6个月平均提高9.2分(95%CI:4.9,13.5,P=.0001)。
  • SF-36身体成分摘要评分在试验过程中无显著差异。
  • SF-36心理成分摘要评分降低2.3分(95%CI:-4.4,-0.1,P=.04)。
  • SF-36活力亚量表降低3.5分(95%CI:-5.6,-1.4,P=.001)。
  • 两治疗组间生活质量评分无差异;线性回归模型显示视力每提高5个字母IND-VFQ评分改善3.2分(95%CI:1.9,4.3;P<.001)。

关键数值与推荐

  • IND-VFQ评分平均提高9.2分(95%CI:4.9,13.5,P=.0001)。
  • SF-36心理成分摘要评分降低2.3分(95%CI:-4.4,-0.1,P=.04)。
  • SF-36活力亚量表降低3.5分(95%CI:-5.6,-1.4,P=.001)。
  • 视力每提高5个字母IND-VFQ评分改善3.2分(95%CI:1.9,4.3;P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the changes in quality of life in noninfectious uveitis patients treated with 2 of the most commonly prescribed antimetabolite treatments. DESIGN: Secondary analysis of a multicenter, block-randomized clinical trial. METHODS: Eighty patients at Aravind Eye Hospitals in Madurai and Coimbatore, India, with noninfectious intermediate, posterior, or panuveitis were randomized to receive oral methotrexate, 25 mg weekly, or oral mycophenolate mofetil, 1 g twice daily, and were followed up monthly for 6 months. Best-corrected visual acuity, Indian Vision Function Questionnaire (IND-VFQ), and Medical Outcomes Study 36-item Short Form Survey (SF-36) were obtained at enrollment and at 6 months (or prior, in the event of early treatment failure). RESULTS: IND-VFQ scores, on average, increased by 9.2 points from trial enrollment to 6 months (95% confidence interval [CI]: 4.9, 13.5, P = .0001). Although the SF-36 physical component summary score did not significantly differ over the course of the trial, the mental component summary score decreased by 2.3 points (95% CI: -4.4, -0.1, P = .04) and the vitality subscale decreased by 3.5 points (95% CI: -5.6, -1.4, P = .001). Quality-of-life scores did not differ between treatment arms. Linear regression modeling showed a 3.2-point improvement in IND-VFQ score for every 5-letter improvement in visual acuity (95% CI: 1.9, 4.3; P < .001). CONCLUSIONS: Although uveitis treatment was associated with increased vision and vision-related quality of life, patient-reported physical health did not change after 6 months of treatment, and mental health decreased. Despite improved visual outcomes, uveitis patients receiving systemic immunosuppressive therapy may experience a deterioration in mental health-related quality of life.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Niemeyer KM, Gonzales JA, Rathinam SR, et al. Quality-of-Life Outcomes From a Randomized Clinical Trial Comparing Antimetabolites for Intermediate, Posterior, and Panuveitis. Am J Ophthalmol. 2017. PMID: 28414043. doi:10.1016/j.ajo.2017.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。